DE3825374C2 - - Google Patents

Info

Publication number
DE3825374C2
DE3825374C2 DE3825374A DE3825374A DE3825374C2 DE 3825374 C2 DE3825374 C2 DE 3825374C2 DE 3825374 A DE3825374 A DE 3825374A DE 3825374 A DE3825374 A DE 3825374A DE 3825374 C2 DE3825374 C2 DE 3825374C2
Authority
DE
Germany
Prior art keywords
mitoxantrone
liposomes
novantron
liposome
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3825374A
Other languages
German (de)
English (en)
Other versions
DE3825374A1 (de
Inventor
Reto Dipl.-Apotheker Dr.Sc.Nat. Kilchberg Ch Schwendener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE3825374A priority Critical patent/DE3825374A1/de
Publication of DE3825374A1 publication Critical patent/DE3825374A1/de
Application granted granted Critical
Publication of DE3825374C2 publication Critical patent/DE3825374C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/32—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by at least three rings
    • C07C225/34—Amino anthraquinones
    • C07C225/36—Amino anthraquinones the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes
DE3825374A 1988-07-26 1988-07-26 Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren Granted DE3825374A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE3825374A DE3825374A1 (de) 1988-07-26 1988-07-26 Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3825374A DE3825374A1 (de) 1988-07-26 1988-07-26 Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren

Publications (2)

Publication Number Publication Date
DE3825374A1 DE3825374A1 (de) 1990-02-01
DE3825374C2 true DE3825374C2 (da) 1990-06-28

Family

ID=6359585

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3825374A Granted DE3825374A1 (de) 1988-07-26 1988-07-26 Komplex aus mindestens einer lipophilen saeure und mitoxantron und/oder bisantren

Country Status (1)

Country Link
DE (1) DE3825374A1 (da)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19818802A1 (de) * 1998-04-27 1999-10-28 Dresden Arzneimittel Stabile Mitoxantron-Lösungen
US7820193B2 (en) 1993-07-19 2010-10-26 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023241A1 (de) * 1990-07-21 1992-01-23 Knoll Ag Stabile wirkstoff-formulierung
DE4208527A1 (de) * 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
EP1674081A1 (de) 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
CN112472699A (zh) * 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
WO2019073296A1 (en) * 2017-10-13 2019-04-18 Race Oncology Ltd. LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR THE LIKE THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3343530A1 (de) * 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820193B2 (en) 1993-07-19 2010-10-26 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
DE19818802A1 (de) * 1998-04-27 1999-10-28 Dresden Arzneimittel Stabile Mitoxantron-Lösungen

Also Published As

Publication number Publication date
DE3825374A1 (de) 1990-02-01

Similar Documents

Publication Publication Date Title
DE69531701T2 (de) Sphingosome mit verbesserter arzneistoffabgage
DE60115045T2 (de) Verbesserte liposomale camptothecine und deren verwendungen
DE69725747T2 (de) Liposome enthaltend cisplatin
DE69907243T2 (de) In liposomen eingeschlossene topoisomerase inhibitoren
US5965156A (en) Amphotericin B liposome preparation
DE69837339T2 (de) Veränderung der Wirkstoffladung in multivesikulären Liposomen
DE60030965T2 (de) Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
DE69935435T2 (de) Mittels Ammoniumsulfatgradient hergestellte liposomale analgetische Zusammensetzungen
DE69732308T2 (de) Arzneistoffverabreichungssystem mit hyaluronsäure
EP0056781A2 (de) Verfahren zur Herstellung von liposomalen Arzneimitteln
DE60110057T2 (de) Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung
DE60222580T2 (de) Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
DE69924004T2 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
DE3825374C2 (da)
EP0461559B1 (de) Wirkstofffreie Liposomen zur Behandlung von Atherosklerose
DE602004011982T2 (de) Verfahren zur Beladung von therapeutischen Mitteln in vorgeformte Liposomen und das dabei erhaltene Produkt
EP0630231B1 (de) Liposomen mit negativer überschussladung
DE60025494T2 (de) Epothilon zusammensetzungen
EP1427393A2 (de) Wirkstoffhaltige liposome
EP0488142B1 (de) Verfahren zur Verkapselung fester oder flüssiger, lipophiler Wirkstoffe zu diesen Wirkstoff enthaltenden Phospholipid-Liposomen sowie Arzneimittel diese Liposomen enthaltend
DE4122744C2 (de) Wäßriges Liposomensystem und Verfahren zu seiner Herstellung
EP0817623B1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
DE4132677C2 (de) Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung
DE19522693A1 (de) Zusammensetzung zur Herstellung feindisperser Systeme und Verfahren zu ihrer Herstellung
EP0611303B1 (de) Carboplatin oder Lobaplatin ENTHALTENDE ZUBEREITUNGEN ZUR ANTITUMORTHERAPIE UND/ODER STIMULIERUNG DES HÄMATOPOETISCHEN SYSTEMS

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
D2 Grant after examination
8364 No opposition during term of opposition